ArticleNature communications2020
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05661110 (Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy), which is not on this map. Cited by 152 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 5 pooled it
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Combined PD1/PDL1 Inhibitor Treatment in Patients of Advanced Gastric Cancer With Peritoneal Metastasis
Who cites it
152 citing papers in PubMed, 5 syntheses or guidelines pooled it, 228 citations in OpenAlex.
- Prognostic Value of Circulating Tumor DNA-Based Minimal Residual Disease for Recurrence-Free Survival in Resectable Gastric Cancer: A Systematic Review and Meta-Analysis with Serial Monitoring Analysis.Digestive diseases and sciences · 2026Pooled it
- Circulating tumor DNA and prognosis in gastric cancer patients undergoing surgery: meta-analysis and trial sequential analysis.Frontiers in oncology · 2026Pooled it
- Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.EBioMedicine · 2024Pooled it
- Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.Cancer medicine · 2023Pooled it
- Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review.JCO precision oncology · 2022Pooled it
- Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.Scientific reports · 2026Trial
- Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.Annals of surgical oncology · 2024Trial
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.Nature medicine · 2023Trial
- Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Trial
- Perioperative Circulating Tumor DNA in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: Molecular Residual Disease, Recurrence Prediction, and a Trial-Ready Framework for Treatment Adaptation.Journal of gastrointestinal cancer · 2026Review
- Postoperative ctDNA in Resectable Gastric Cancer: Prognostically Powerful, but Not Yet Actionable.Digestive diseases and sciences · 2026Article
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review.Journal of clinical medicine · 2026Review
- Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers.International journal of molecular sciences · 2026Review
- Orthogonal nanopores cross-validation for multiplex single-molecule profiling.Chemical science · 2026Article
- Circulating Tumor DNA Sequencing for Early Diagnosis and Detection of Treatment Response, Minimal Residual Disease, and Recurrence in Gastroesophageal Cancer.Journal of gastrointestinal cancer · 2026Review
- Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Circulating cell-free mtDNA fragmentomics for early detection of gastric cancer and precancerous lesions.Cell reports. Medicine · 2026Article
- Molecular features unique to circulating tumor DNA enable the tumor-naïve liquid biopsy of glioblastoma.NPJ precision oncology · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 3 countries.
Alessandro Leal *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-7967-3213
Nicole C T van Grieken *Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0001-9992-0760
Doreen N PalsgroveThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Jillian PhallenThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Jamie E MedinaThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0002-6124-0548
Carolyn HrubanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Mark A M BroeckaertDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Valsamo AnagnostouThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-9480-3047
Vilmos AdleffThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Daniel C BruhmThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0002-8436-501X
Jenna V CanzonieroDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Jacob FikselThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Marianne NordsmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Fabienne A R M WarmerdamDepartment of Medical Oncology, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, Netherlands.
Henk M W VerheulDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Dick Johan van SpronsenDepartment of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.ORCID http://orcid.org/0000-0003-1397-0236
Laurens V BeerepootDepartment of Internal Medicine, St. Elisabeth-Tweesteden Ziekenhuis, Tilburg, Netherlands.ORCID http://orcid.org/0000-0002-3040-4626
Maud M GeenenDepartment of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
Johanneke E A PortieljeDepartment of Internal Medicine, HAGA hospital, The Hague, Netherlands.
Edwin P M JansenDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-8582-8100
Johanna van SandickDepartment of Surgery, Netherlands Cancer Institute, Amsterdam, Netherlands.
Elma Meershoek-Klein KranenbargDepartment of Surgery, Leiden University Medical Center, Leiden, Netherlands.ORCID http://orcid.org/0000-0002-1750-2221
Hanneke W M van LaarhovenDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Donald L van der PeetDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Cornelis J H van de VeldeDepartment of Surgery, Leiden University Medical Center, Leiden, Netherlands.
Marcel VerheijDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Remond FijnemanDepartment of Pathology, Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0003-2076-5521
Robert B ScharpfThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Gerrit A MeijerDepartment of Pathology, Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Annemieke CatsDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Victor E VelculescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. velculescu@jhmi.edu.ORCID http://orcid.org/0000-0003-1195-438X
Johns Hopkins University · USThe Netherlands Cancer Institute · NLAmsterdam University Medical Centers · NLLeiden University Medical Center · NLAarhus University Hospital · DKElisabeth-TweeSteden Ziekenhuis · NLOLVG · NLRadboud University Nijmegen · NLZuyderland Medisch Centrum · NL
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6MTraining Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7MPredoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6MTraining Program In Cellular and Molecular MedicineT32GM135457 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAJINI RAO · 2020 to 2026
$5.4MECOG-ACRIN Thoracic Malignancies Integrated Translational Science CenterUG1CA233259 · NCI · EMORY UNIVERSITY · PI CARBONE, DAVID P., LEAL, TICIANA · 2019 to 2025
$5.1MLarge-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3MOpportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6MEIF | Stand Up To Cancer (SU2C) SU2C-AACR-DT1415NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA121113NCI NIH HHS T32 CA193145NCI NIH HHS UG1 CA233259NIGMS NIH HHS T32 GM007814NIGMS NIH HHS T32 GM008752NIGMS NIH HHS T32 GM135457U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA121113U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA193145U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA233259
Abstract
Liquid biopsies are providing new opportunities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounded through identification of alterations arising from clonal hematopoiesis. Here, we identify circulating tumor-derived DNA (ctDNA) alterations through ultrasensitive targeted sequencing analyses of matched cfDNA and white blood cells from the same patient. We apply this approach to analyze samples from patients in the CRITICS trial, a phase III randomized controlled study of perioperative treatment in patients with operable gastric cancer. After filtering alterations from matched white blood cells, the presence of ctDNA predicts recurrence when analyzed within nine weeks after preoperative treatment and after surgery in patients eligible for multimodal treatment. These analyses provide a facile method for distinguishing ctDNA from other cfDNA alterations and highlight the utility of ctDNA as a predictive biomarker of patient outcome to perioperative cancer therapy and surgical resection in patients with gastric cancer.
Indexed as
Sequence Analysis, DNACell-Free Nucleic AcidsDNA, NeoplasmHematopoiesisHumansLeukocytesNeoplasm Recurrence, LocalPrognosisProof of Concept StudyRandomized Controlled Trials as TopicStomach NeoplasmsSurvival AnalysisCell-Free Nucleic AcidsDNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05661110ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.